BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 32023727)

  • 1. [Effect of nilotinib on pregnancy outcome in female patients with chronic myeloid leukemia].
    Zhao HF; Song YP; Li Z; Zhou J; Yu FK; Gui RR; Zu YL; Wei XD; Zhang Y
    Zhonghua Xue Ye Xue Za Zhi; 2019 Dec; 40(12):986-989. PubMed ID: 32023727
    [No Abstract]   [Full Text] [Related]  

  • 2. [Clinical analysis about the management and the perinatal outcomes of pregnancy with chronic myeloid leukemia].
    Wang DP; Liang MY; Zhang XH; Wang SM
    Zhonghua Fu Chan Ke Za Zhi; 2010 Oct; 45(10):735-9. PubMed ID: 21176552
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Two successful pregnancies in a woman with chronic myeloid leukemia exposed to nilotinib during the first trimester of her second pregnancy: case study.
    Conchon M; Sanabani SS; Bendit I; Santos FM; Serpa M; Dorliac-Llacer PE
    J Hematol Oncol; 2009 Oct; 2():42. PubMed ID: 19807918
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Planned Pregnancy in Female Patients with Chronic Myeloid Leukemia Receiving Tyrosine Kinase Inhibitor Therapy.
    Dou X; Qin Y; Huang X; Jiang Q
    Oncologist; 2019 Nov; 24(11):e1141-e1147. PubMed ID: 31186377
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management of chronic myeloid leukemia during pregnancy among patients treated with a tyrosine kinase inhibitor: a single-Center experience.
    Assi R; Kantarjian H; Keating M; Pemmaraju N; Verstovsek S; Garcia-Manero G; Ravandi F; Borthakur G; Dahl J; Jabbour E; Cortes JE
    Leuk Lymphoma; 2021 Apr; 62(4):909-917. PubMed ID: 33283580
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Pregnancy outcome among patients with chronic myelogenous leukemia treated with tyrosine kinase inhibitors].
    Jiang Q; Jiang B; Chen SS; Jiang H; Qin YZ; Lai YY; Shi HX; Huang XJ
    Zhonghua Xue Ye Xue Za Zhi; 2012 Jan; 33(1):6-9. PubMed ID: 22575184
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Evaluation of impact of baseline ABL kinase domain point mutations on response to nilotinib in imatinib-resistant or-intolerant patients with chronic myeloid leukemia].
    Jiang H; Chen SS; Jiang B; Jiang Q; Qin YZ; Lai YY; Liu YR; Huang XJ
    Zhonghua Xue Ye Xue Za Zhi; 2012 Feb; 33(2):123-6. PubMed ID: 22730663
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Switching to nilotinib is associated with deeper molecular responses in chronic myeloid leukemia chronic phase with major molecular responses to imatinib: STAT1 trial in Japan.
    Noguchi S; Nakaseko C; Nishiwaki K; Ogasawara H; Ohishi K; Tokuhira M; Noguchi M; Kimura H; Handa H; Mitani K; Miura M; Wakita H; Takahashi N;
    Int J Hematol; 2018 Aug; 108(2):176-183. PubMed ID: 29713954
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pregnancy among patients with chronic myeloid leukemia treated with imatinib.
    Ault P; Kantarjian H; O'Brien S; Faderl S; Beran M; Rios MB; Koller C; Giles F; Keating M; Talpaz M; Cortes J
    J Clin Oncol; 2006 Mar; 24(7):1204-8. PubMed ID: 16446320
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Analysis of the efficacy and influencing factors of nilotinib or dasatinib as second- or third-line treatment in patients with chronic myeloid leukemia in the chronic phase and accelerated phase].
    Yuan T; Lai YY; Qin YZ; Shi HX; Huang XJ; Hou Y; Jiang Q
    Zhonghua Xue Ye Xue Za Zhi; 2020 Feb; 41(2):93-99. PubMed ID: 32135623
    [No Abstract]   [Full Text] [Related]  

  • 11. Pregnancy outcome in chronic myeloid leukemia patients on imatinib therapy.
    Mukhopadhyay A; Dasgupta S; Kanti Ray U; Gharami F; Bose CK; Mukhopadhyay S
    Ir J Med Sci; 2015 Mar; 184(1):183-8. PubMed ID: 24590821
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Fertility and disease outcomes in patients with chronic myeloid leukemia].
    Dou XL; Qin YZ; Shi HX; Lai YY; Hou Y; Huang XJ; Jiang Q
    Zhonghua Xue Ye Xue Za Zhi; 2019 Dec; 40(12):980-985. PubMed ID: 32023726
    [No Abstract]   [Full Text] [Related]  

  • 13. Nilotinib: a second-generation tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia.
    Deremer DL; Ustun C; Natarajan K
    Clin Ther; 2008 Nov; 30(11):1956-75. PubMed ID: 19108785
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment-Free Remission After Second-Line Nilotinib Treatment in Patients With Chronic Myeloid Leukemia in Chronic Phase: Results From a Single-Group, Phase 2, Open-Label Study.
    Mahon FX; Boquimpani C; Kim DW; Benyamini N; Clementino NCD; Shuvaev V; Ailawadhi S; Lipton JH; Turkina AG; De Paz R; Moiraghi B; Nicolini FE; Dengler J; Sacha T; Takahashi N; Fellague-Chebra R; Acharya S; Wong S; Jin Y; Hughes TP
    Ann Intern Med; 2018 Apr; 168(7):461-470. PubMed ID: 29459949
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Clinical characteristics of vascular adverse events and significance of peripheral artery disease as a risk factor in chronic myeloid leukemia patients treated with nilotinib].
    Sumi M; Sato K; Uematsu N; Kawaguchi H; Shishido T; Kaiume H; Takeda W; Kirihara T; Ueki T; Hiroshima Y; Ueno M; Ichikawa N; Urasawa N; Kobayashi H
    Rinsho Ketsueki; 2018; 59(2):137-144. PubMed ID: 29515064
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of nilotinib therapy in patients with newly diagnosed chronic myeloid leukemia in the chronic phase.
    Tokuhira M; Kimura Y; Sugimoto K; Nakazato T; Ishikawa M; Fujioka I; Takaku T; Iriyama N; Sato E; Fujita H; Hatta Y; Komatsu N; Asou N; Kizaki M; Kawaguchi T
    Med Oncol; 2018 Feb; 35(3):38. PubMed ID: 29442179
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pregnancies in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitor.
    Zhou L; You JH; Wu W; Li JM; Shen ZX; Wang AH
    Leuk Res; 2013 Oct; 37(10):1216-21. PubMed ID: 23937984
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcomes with frontline nilotinib treatment in Turkish patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase.
    Saydam G; Haznedaroglu IC; Kaynar L; Yavuz AS; Ali R; Guvenc B; Akay OM; Baslar Z; Ozbek U; Sonmez M; Aydin D; Pehlivan M; Undar B; Dagdas S; Ayyildiz O; Akkaynak DZ; Dag IM; Ilhan O
    Expert Opin Pharmacother; 2016 Oct; 17(14):1851-8. PubMed ID: 27501474
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of residual CD34(+) Ph(+) progenitor cells in chronic myeloid leukemia patients who have complete cytogenetic response during first-line nilotinib therapy.
    Defina M; Ippoliti M; Gozzetti A; Abruzzese E; Castagnetti F; Crupi R; Tiribelli M; Breccia M; Salvucci M; Aprile L; Baratè C; Gozzini A; Rosti G; Lauria F; Bocchia M
    Cancer; 2012 Nov; 118(21):5265-9. PubMed ID: 22517301
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Successful delivery after planned discontinuation of imatinib in a patient with chronic myeloid leukemia.
    Kobayashi K; Takebayashi C; Miyata S; Narimatsu H; Kami M
    Intern Med; 2009; 48(5):369-71. PubMed ID: 19252364
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.